Abstract

Similar articles

• [The role of angiogenesis in renal carcinoma].

  Bussolati B, Satolli MA, Camussi G.Bussolati B, et al.G Ital Nefrol. 2008 May-Jun;25(3):297-305.G Ital Nefrol. 2008.PMID:18473301Review.Italian.
• Signaling inhibitors in metastatic renal cell carcinoma.

  Escudier B.Escudier B.Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.Cancer J. 2008.PMID:18836338
• [Angiogenesis and renal cell carcinoma].

  Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O.Billemont B, et al.Bull Cancer. 2007 Jul;94 Spec No:S232-40.Bull Cancer. 2007.PMID:17846009Review.French.
• Targeted therapy for metastatic renal cell carcinoma.

  Motzer RJ, Bukowski RM.Motzer RJ, et al.J Clin Oncol. 2006 Dec 10;24(35):5601-8. doi: 10.1200/JCO.2006.08.5415.J Clin Oncol. 2006.PMID:17158546Review.
• Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

  Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL.Alfaro C, et al.Br J Cancer. 2009 Apr 7;100(7):1111-9. doi: 10.1038/sj.bjc.6604965. Epub 2009 Mar 10.Br J Cancer. 2009.PMID:19277038Free PMC article.

Cited by

• Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis.

  Tabana Y, Okoye IS, Siraki A, Elahi S, Barakat KH.Tabana Y, et al.Front Oncol. 2021 Mar 5;11:628138. doi: 10.3389/fonc.2021.628138. eCollection 2021.Front Oncol. 2021.PMID:33747948Free PMC article.Review.
• Metastatic renal cell carcinoma presenting as multiple cutaneous lesions visualized through reflectance confocal microscopy.

  Razi S, Ouellette S, Khan S, Rao B.Razi S, et al.Clin Case Rep. 2023 Jun 7;11(6):e7486. doi: 10.1002/ccr3.7486. eCollection 2023 Jun.Clin Case Rep. 2023.PMID:37305867Free PMC article.
• The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.

  Cetin B, Gonul II, Buyukberber S, Afsar B, Gumusay O, Algın E, Turan N, Ozet A, Benekli M, Coskun U.Cetin B, et al.Tumour Biol. 2015 Nov;36(11):8471-8. doi: 10.1007/s13277-015-3589-6. Epub 2015 May 31.Tumour Biol. 2015.PMID:26026587
• VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.

  Liu F, Chen X, Peng E, Guan W, Li Y, Hu Z, Ye Z, Zhuang Q.Liu F, et al.J Huazhong Univ Sci Technolog Med Sci. 2011 Dec;31(6):799-806. doi: 10.1007/s11596-011-0680-0. Epub 2011 Dec 16.J Huazhong Univ Sci Technolog Med Sci. 2011.PMID:22173502
• MET Inhibition in Clear Cell Renal Cell Carcinoma.

  Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B.Xie Z, et al.J Cancer. 2016 Jun 18;7(10):1205-14. doi: 10.7150/jca.14604. eCollection 2016.J Cancer. 2016.PMID:27390595Free PMC article.

Publication types

• Review

MeSH terms

• Angiogenesis Inhibitors / pharmacology
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / pharmacology
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents / pharmacology*
• Benzenesulfonates / adverse effects
• Benzenesulfonates / pharmacology
• Bevacizumab
• Carcinoma, Renal Cell / blood supply
• Carcinoma, Renal Cell / drug therapy*
• Carcinoma, Renal Cell / metabolism*
• Clinical Trials as Topic
• Humans
• Indoles / adverse effects
• Indoles / pharmacology
• Kidney Neoplasms / blood supply
• Kidney Neoplasms / drug therapy*
• Kidney Neoplasms / metabolism*
• Neovascularization, Pathologic / drug therapy
• Neovascularization, Pathologic / metabolism
• Niacinamide / analogs & derivatives
• Phenylurea Compounds
• Protein Kinase Inhibitors / pharmacology
• Pyridines / adverse effects
• Pyridines / pharmacology
• Pyrroles / adverse effects
• Pyrroles / pharmacology
• Sorafenib
• Sunitinib
• Vascular Endothelial Growth Factor A / antagonists & inhibitors*
• Vascular Endothelial Growth Factor A / metabolism

Substances

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Benzenesulfonates
• Indoles
• Phenylurea Compounds
• Protein Kinase Inhibitors
• Pyridines
• Pyrroles
• Vascular Endothelial Growth Factor A
• Niacinamide
• Bevacizumab
• Sorafenib
• Sunitinib

Related information

• MedGen
• PubChem Compound
• PubChem Compound (MeSH Keyword)
• PubChem Substance

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information